Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients

J. R. Wingard, W. G. Merz, M. G. Rinaldi, C. B. Miller, Judith Karp, R. Saral

Research output: Contribution to journalArticle

Abstract

Because the use of fluconazole prophylaxis had been associated with an increased rate of Candida krusei infections at The Johns Hopkins Oncology Center, early empiric amphotericin B plus flucytosine were given to febrile neutropenic patients colonized by C. krusei. By this practice, the proportion of fungemias attributable to C. krusei was low (12.5%) in patients receiving fluconazole over a 6-month interval. However, Torulopsis (Candida) glabrata assumed a much higher proportion of fungemias (75%) among patients receiving fluconazole. In vitro susceptibility testing combined with this clinical experience suggests that some T. glabrata isolates are not susceptible to fluconazole and can cause breakthrough infections in patients receiving fluconazole.

Original languageEnglish (US)
Pages (from-to)1847-1849
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume37
Issue number9
StatePublished - 1993
Externally publishedYes

Fingerprint

Candida glabrata
Fluconazole
Bone Marrow
Transplants
Fungemia
Infection
Flucytosine
Amphotericin B
Candida
Fever

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. / Wingard, J. R.; Merz, W. G.; Rinaldi, M. G.; Miller, C. B.; Karp, Judith; Saral, R.

In: Antimicrobial Agents and Chemotherapy, Vol. 37, No. 9, 1993, p. 1847-1849.

Research output: Contribution to journalArticle

Wingard, J. R. ; Merz, W. G. ; Rinaldi, M. G. ; Miller, C. B. ; Karp, Judith ; Saral, R. / Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. In: Antimicrobial Agents and Chemotherapy. 1993 ; Vol. 37, No. 9. pp. 1847-1849.
@article{4f23a26e9980488881f51f88ecc181be,
title = "Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients",
abstract = "Because the use of fluconazole prophylaxis had been associated with an increased rate of Candida krusei infections at The Johns Hopkins Oncology Center, early empiric amphotericin B plus flucytosine were given to febrile neutropenic patients colonized by C. krusei. By this practice, the proportion of fungemias attributable to C. krusei was low (12.5{\%}) in patients receiving fluconazole over a 6-month interval. However, Torulopsis (Candida) glabrata assumed a much higher proportion of fungemias (75{\%}) among patients receiving fluconazole. In vitro susceptibility testing combined with this clinical experience suggests that some T. glabrata isolates are not susceptible to fluconazole and can cause breakthrough infections in patients receiving fluconazole.",
author = "Wingard, {J. R.} and Merz, {W. G.} and Rinaldi, {M. G.} and Miller, {C. B.} and Judith Karp and R. Saral",
year = "1993",
language = "English (US)",
volume = "37",
pages = "1847--1849",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients

AU - Wingard, J. R.

AU - Merz, W. G.

AU - Rinaldi, M. G.

AU - Miller, C. B.

AU - Karp, Judith

AU - Saral, R.

PY - 1993

Y1 - 1993

N2 - Because the use of fluconazole prophylaxis had been associated with an increased rate of Candida krusei infections at The Johns Hopkins Oncology Center, early empiric amphotericin B plus flucytosine were given to febrile neutropenic patients colonized by C. krusei. By this practice, the proportion of fungemias attributable to C. krusei was low (12.5%) in patients receiving fluconazole over a 6-month interval. However, Torulopsis (Candida) glabrata assumed a much higher proportion of fungemias (75%) among patients receiving fluconazole. In vitro susceptibility testing combined with this clinical experience suggests that some T. glabrata isolates are not susceptible to fluconazole and can cause breakthrough infections in patients receiving fluconazole.

AB - Because the use of fluconazole prophylaxis had been associated with an increased rate of Candida krusei infections at The Johns Hopkins Oncology Center, early empiric amphotericin B plus flucytosine were given to febrile neutropenic patients colonized by C. krusei. By this practice, the proportion of fungemias attributable to C. krusei was low (12.5%) in patients receiving fluconazole over a 6-month interval. However, Torulopsis (Candida) glabrata assumed a much higher proportion of fungemias (75%) among patients receiving fluconazole. In vitro susceptibility testing combined with this clinical experience suggests that some T. glabrata isolates are not susceptible to fluconazole and can cause breakthrough infections in patients receiving fluconazole.

UR - http://www.scopus.com/inward/record.url?scp=0027216833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027216833&partnerID=8YFLogxK

M3 - Article

C2 - 8239594

AN - SCOPUS:0027216833

VL - 37

SP - 1847

EP - 1849

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 9

ER -